In a recent case series, involving 5 moderate-to-severe HS patients (40% female, 2 of whom had received prior anti-TNF-α therapy) treated with 100 mg tildrakizumab at weeks 0 and 4 and 200 mg every 4 weeks thereafter, an improvement in abscess and nodule count was demonstrated in all HS patients at week 8 compared to baseline (at week 20, 2 patients reported ongoing improvement). This evidence concerns the gene TNF and abscess.